

AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

1. (Currently Amended) A method for the treatment of a disease in a mammalian subject comprising administering to said subject an effective amount of a mammalian intermediary metabolite, wherein said intermediary metabolite is a $[[\beta-]]$ glycosylceramide, and wherein said the pathogenesis of the disease is derived from an inflammatory immune response colitis, immune-mediated hepatitis, nonalcoholic steatohepatitis, diabetes or melanoma.

2-124. (Canceled)

125. (Currently Amended) The method of claim 1, wherein said $[[\beta-]]$ glycosylceramide is comprises a glucosylceramide or galactosylceramide.

126-150. (Canceled)

151. (Currently Amended) The method of claim ~~[[s]] 1, 11, 43, 44, 45, 54, 59, 60 or 97~~ wherein said administering step comprises oral, intravenous, intraperitoneal, intramuscular, parenteral, transdermal, intravaginal, intranasal, mucosal, sublingual, topical, rectal or subcutaneous administration, or any combination thereof.

152-205. (Canceled)

206. (New) The method of claim 1, wherein said glycosylceramide is a monosaccharide ceramide.

207. (New) The method of claim 1, wherein said disease is colitis.

Enz-64(CIP)

208. (New/Withdrawn) The method of claim 1, wherein said disease is immune-mediated hepatitis.

209. (New/Withdrawn) The method of claim 1, wherein said disease is nonalcoholic steatohepatitis.

210. (New/Withdrawn) The method of claim 1, wherein said disease is diabetes.

211. (New/Withdrawn) The method of claim 1, wherein said disease is melanoma.